Pradeep Mammen, MD
Advanced Heart Failure and Transplant Cardiology · Kansas City, KSNPI 1386609196
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,400 of the $17,577 with a category attached, or 64.9%. 26 manufacturers reported payments, led by Sarepta Therapeutics, Inc. at 41.2% of the total. Reporting peaked in 2023 at $7,878 and has fallen 50.9% since, to $3,865 in 2025.
Across 98 payments — averaging $179.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$7K
- PTC Therapeutics, Inc.$4K
- Abbott$3K
- Abiomed$476
- Impulse Dynamics (USA) Inc.$438
- Merck$257
- plus $1K from 20 others
Across 1 payment — averaging $2025.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$2K
What the payments were for
- Consulting fees$11,40065%
- Travel & lodging$2,48914%
- Food & beverage$3,68921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 5 | $7,237 |
| PTC Therapeutics, Inc. | 3 | $4,400 |
| Abbott | 29 | $3,305 |
| Abiomed | 3 | $476 |
| Impulse Dynamics (USA) Inc. | 6 | $438 |
| Merck | 15 | $257 |
| Medtronic | 4 | $197 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $181 |
| Endotronix, Inc. | 2 | $157 |
| Heartflow, Inc. | 1 | $142 |
| Paragonix Technologies, Inc. | 1 | $135 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $124 |
| Boston Scientific | 1 | $123 |
| Boehringer Ingelheim | 5 | $79 |
| AstraZeneca | 4 | $65 |
| Edwards Lifesciences | 1 | $41 |
| Procyrion, Inc. | 1 | $40 |
| Ancora Heart, Inc. | 1 | $36 |
| Novo Nordisk | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Pfizer | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$1,507
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,311
- Impella$476
- OPTIMIZER$312
- Paragonix SherpaPak Cardiac Transport System$271
- SherpaCool Box$271
- NURTEC ODT$144
- FFRct$142
- Shipper Box$135
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$130
- AVVIGO Guidance System$123
- RESOLUTE ONYX$119
How this compares
Too few advanced heart failure and transplant cardiology providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 156 | $176,726 |
| JardianceEmpagliflozin | 64 | $86,400 |
| FarxigaDapagliflozin Propanediol | 49 | $51,628 |
| EliquisApixaban | 37 | $48,511 |
| XareltoRivaroxaban | 11 | $13,259 |
| Praluent PenAlirocumab | 19 | $10,907 |
| Envarsus XrTacrolimus | 25 | $4,442 |
| Sirolimus | 16 | $3,697 |
| Mycophenolic AcidMycophenolate Sodium | 19 | $2,532 |
| Midodrine Hcl | 16 | $2,437 |
| Tacrolimus | 18 | $2,362 |
| Metoprolol Succinate | 166 | $2,123 |
| Isosorbide Dinitrate | 48 | $1,645 |
| Bumetanide | 41 | $1,472 |
| Carvedilol | 93 | $1,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $79 | $86,40064 claims |
| AstraZenecaFarxiga | $65 | $51,62849 claims |
| PfizerEliquis | $15 | $48,51137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Kansason file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Kansas City
- Zubair ShahKansas City$387K
- Hirak ShahKansas City$29K
- Tarun DaliaKansas City$16K
- Michelle DimzaKansas City$12K
- Raja ZaghlolKansas City$5K
- Mohamed El KhashabKansas City$4K
- Jane TitteringtonKansas City$4K
- Paola RoldanKansas City$3K
- Daniel HarrisonKansas City$1K
- Deepthi VodnalaOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.